Methotrexate

Regulatory approvals and trial activity for upadacitinib (Rinvoq) affect availability and prescribing patterns for immunomodulatory treatment options used across autoimmune and inflammatory diseases, including IBD.

Patients and clinicians often need real-world data on how methotrexate is actually used in IBD outside trials—this study shows it’s commonly paired with biologics, usually given subcutaneously, and has a median use of...

People with IBD and their clinicians need to know whether common IBD treatments change COVID-19 risk or should be stopped. This review provides practical recommendations (continue most maintenance drugs; avoid systemic...

This FDA drug-label update describes approved uses and safety warnings for tofacitinib, a JAK inhibitor used in immune-mediated diseases including ulcerative colitis. The boxed warnings highlight serious infection and...

Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.

FDA drug-label updates change how a medicine should be used and monitored. For people with ulcerative colitis and other immune-mediated diseases, this label highlights safety risks and limits on combining tofacitinib...

Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...

Methotrexate is commonly used in IBD, often with biologics, but real‑world data on how long patients stay on it, typical dosing, and safety in large contemporary cohorts are limited.

Market reports can signal which drugs, companies, and biosimilars are becoming more available and may affect access and cost. Announcements about biosimilars could influence treatment affordability and prescribing...

This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.

This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.

The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...